Optimer binders against three therapeutic targets to support drug validation and potential clinical trial applications ...

Touchlight has expanded its mbDNA platform with the introduction of three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA.

Kuvalanka brings over 20 years of experience in biopharmaceutical leadership, including finance, business development, and corporate strategy.

Agreement includes approximately $350 million in cash and upfront technology license fees for Evotec’s continuous manufacturing platform.

Ailux has announced a strategic collaboration with Eli Lilly and Company to accelerate the discovery and development of bispecific antibodies.

The research collaboration agreement will offer new chemical entity (NCE)-eligible pro-drug candidates to people affected by blinding eye conditions.

Simtra BioPharma Solutions is advancing a dual-continent expansion aimed at boosting capacity for sterile injectable drugs.

To develop monoclonal antibody biomanufacturing innovations and produce an anti-filovirus Medical Countermeasure.

Merck has reached an agreement with Dr. Falk Pharma to discontinue an existing contract concerning co-development and co-commercialization rights in certain territories for MK-8690.

Magnet Biomedicine, a biopharmaceutical company, has appointed Bharat Reddy, Ph.D., as its new Chief Business Officer.

Boehringer Ingelheim and CDR-Life have announced a new global licensing agreement to develop CDR-Life’s CDR111 for autoimmune diseases.

Strategic financing will advance development of sac-TMT while Merck continues to progress its expansive pipeline.